Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third quarter of 2023.
- The company reported a net loss of $227 million for the third quarter, compared to a profit of $141 million a year earlier
- On a per-share basis, it was a loss of $1.26 for the March quarter vs. earnings of $0.78 in the year-ago quarter
- The adjusted net loss was $0.09 per share, compared to net income of $1.04 per share in Q3 2022
- Third-quarter net revenue decreased 19% year-over-year to $1.04 billion
- Q3 adjusted EBITDA came in at $105 million, which is down 69% from the corresponding period of 2022
- For fiscal 2023, the management expects net revenue to be in the range of $4.225 billion to $4.325 billion
- The forecast for full-year adjusted net income is $169-210 million
Most Popular
Trxade Health Inc. (NASDAQ: MEDS) Q1 2024 Research Summary
Trxade Health, Inc. (NASDAQ: MEDS) is a drug procurement and delivery platform that digitalizes the retail pharmacy experience. The company has a growing network of suppliers and partnerships with independent
Earnings Preview: Walmart (WMT) expected to report sales and profit gains in Q1
Over the years, Walmart Inc. (NYSE: WMT) has constantly diversified while maintaining its dominance in the retail world. The company is preparing to report financial results for the first three
After a positive year, what’s in the cards for Electronic Arts (EA) in FY25
Electronic Arts (NASDAQ: EA) ended fiscal 2024 on a mixed note, reporting lower revenues and improved bottom-line performance for the fourth quarter. The stock declined following the announcement as earnings
